Mouse platforms jostle for slice of humanized antibody market

Riding an emerging wave of fully human antibody therapeutics, Sanofi and partner Regeneron Pharmaceuticals announced positive phase 1b proof-of-concept results for their interleukin-4 receptor monoclonal antibody dupilumab in atopic dermatitis. Paris-based Sanofi and Regeneron of Tarrytown NY gave t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2013-04, Vol.31 (4), p.267-268
1. Verfasser:	Moran, Nuala
Format:	Artikel
Sprache:	eng
Schlagworte:	631/61/51/1568 692/308/153 706/703 Agriculture Analysis Animal experimentation Animals Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Bioinformatics Biomedical Engineering/Biotechnology Biomedicine Biotechnology Cytokines Dermatitis Drug Industry - economics Drug Industry - legislation & jurisprudence Genetic Engineering - economics Health aspects Humans Intellectual Property Life Sciences Marketing - economics Marketing - legislation & jurisprudence Mice Mice, Transgenic Monoclonal antibodies news Pharmaceutical research Pharmaceuticals Product development
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Riding an emerging wave of fully human antibody therapeutics, Sanofi and partner Regeneron Pharmaceuticals announced positive phase 1b proof-of-concept results for their interleukin-4 receptor monoclonal antibody dupilumab in atopic dermatitis. Paris-based Sanofi and Regeneron of Tarrytown NY gave the news at the American Academy of Dermatology meeting in Miami FL in March.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt0413-267